Bioventus (BVS) Registration Filing summary

Company overview and business model

• Operates as a global medical device company focused on minimally invasive, cost-efficient treatments that enhance the body's natural healing process.

• Product portfolio includes pain treatments, surgical solutions, and restorative therapies, with 88% of net sales from the U.S. and 12% from international markets in 2023.

• Incorporated in Delaware in 2015, with principal offices in Durham, North Carolina.

Risk factors and disclosures

• Faces risks from potential divestiture of the Advanced Rehabilitation business, cost savings initiatives, and new therapy launches.

• Subject to risks including debt covenant compliance, supply chain disruptions, product liability, regulatory changes, and cybersecurity threats.

• Dilution risk exists due to potential issuance of Class A common stock upon exchange of LLC Interests, which could impact market price.

• Market and industry data are based on independent sources but are not guaranteed for accuracy.

Use of proceeds and capital allocation

• Net proceeds from company-offered securities will be used as specified in future prospectus supplements.

• No proceeds will be received from the sale of Class A common stock by selling securityholders.